# Study Comparing Efficacy of Doxorubicin With Trabectedin Followed by Trabectedin Versus Doxorubicine in Patients With Leiomyosarcoma

> **NCT02997358** · PHASE3 · COMPLETED · sponsor: **Gustave Roussy, Cancer Campus, Grand Paris** · enrollment: 150 (actual)

## Conditions studied

- Uterine or Soft Tissue Leiomyosarcoma

## Interventions

- **DRUG:** Doxorubicin
- **DRUG:** Trabectedin

## Key facts

- **NCT ID:** NCT02997358
- **Lead sponsor:** Gustave Roussy, Cancer Campus, Grand Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-18
- **Primary completion:** 2021-07-28
- **Final completion:** 2021-07-28
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2021-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02997358

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02997358, "Study Comparing Efficacy of Doxorubicin With Trabectedin Followed by Trabectedin Versus Doxorubicine in Patients With Leiomyosarcoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02997358. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*